Pyxis Oncology secured up to $114 million through a private placement led by BVF Partners to fund the development of its cancer drug MICVO. The financing will extend the company's cash runway into Q2 2027, supporting ongoing trials for head and neck squamous cell carcinoma. Updated Phase 1 monotherapy data is expected in Fall 2026, with combination therapy data due in Q4 2026. This funding strengthens Pyxis's ability to advance MICVO toward regulatory and clinical milestones, aiming to improve treatment for difficult cancers.
Ripple has signed a multi-year sponsorship with University of Florida Athletics, starting the 2026 football season, featuring XRP branding at Ben Hill Griffin Stadium, known as "The Swamp." The deal, estimated at up to $5 million annually, includes f...
DASH surged 17.5% to $56.85, its highest since May, driven by a rally in privacy coins and Grayscale's spot Zcash ETF surpassing $400M in assets. The token gained about 85% from mid-August lows near $30, supported by bullish technical signals like a ...
Pineapple Financial, a mortgage lender listed on NYSE American, has tokenized over $1 billion in residential mortgage data on the Injective blockchain, marking a major step in blending traditional finance with blockchain technology. The project start...
Polymarket plans a $1 billion funding round valuing the prediction market platform at $21 billion, led by Donald Trump Jr.'s 1789 Capital. Cronos reversed its blockchain after a $75 million exploit in the Tectonic lending protocol, restoring the netw...
Investment-grade credit default swap (CDS) prices fell below 50 basis points, nearing lows not seen since February 2020, indicating improved credit market confidence. Meanwhile, the VIX volatility index dropped below 14 for the first time since Decem...
